JO
URGN icon

John Overdeck’s UroGen Pharma URGN Stock Holding History

John Overdeck’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.48M Sell
148,963
-28,938
-16% -$784K ﹤0.01% 2057
2026
Q1 		$3.2M Sell
177,901
-63,312
-26% -$1.27M ﹤0.01% 2390
2025
Q4 		$5.65M Sell
241,213
-144,990
-38% -$3.15M 0.01% 1601
2025
Q3 		$7.7M Buy
386,203
+196,791
+104% +$3.53M 0.01% 1116
2025
Q2 		$2.59M Buy
189,412
+172,124
+996% +$1.65M ﹤0.01% 1651
2025
Q1 		$191K Sell
17,288
-39,607
-70% -$422K ﹤0.01% 2862
2024
Q4 		$606K Sell
56,895
-30,139
-35% -$361K ﹤0.01% 2446
2024
Q3 		$1.11M Sell
87,034
-13,388
-13% -$199K ﹤0.01% 2065
2024
Q2 		$1.69M Buy
100,422
+19,925
+25% +$283K ﹤0.01% 1660
2024
Q1 		$1.21M Sell
80,497
-50,258
-38% -$821K ﹤0.01% 1834
2023
Q4 		$1.96M Buy
130,755
+10,541
+9% +$137K ﹤0.01% 1567
2023
Q3 		$1.68M Buy
120,214
+100,399
+507% +$1.61M ﹤0.01% 1531
2023
Q2 		$205K Buy
+19,815
New +$219K ﹤0.01% 2636
2021
Q2 		– Sell
-19,800
Closed -$386K – 4590
2021
Q1 		$386K Buy
+19,800
New +$420K ﹤0.01% 3152
2018
Q4 		– Sell
-5,954
Closed -$281K – 3548
2018
Q3 		$281K Sell
5,954
-9,022
-60% -$419K ﹤0.01% 2811
2018
Q2 		$745K Buy
+14,976
New +$872K ﹤0.01% 2362
2018
Q1 		– Sell
-7,436
Closed -$277K – 3536
2017
Q4 		$277K Buy
+7,436
New +$265K ﹤0.01% 2766

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

John Overdeck's URGN Position: Q2 2026 in Review

John Overdeck reduced its UroGen Pharma (URGN) stake by 16% in Q2 2026, selling an estimated $784K and leaving 148,963 shares worth $5.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2057.

John Overdeck first reported a position in URGN in Q4 2017 and has held it in 17 quarters since. The position peaked at $7.7M in Q3 2025. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • John Overdeck held 148,963 shares of UroGen Pharma worth $5.48M as of Q2 2026.
  • John Overdeck sold 28,938 UroGen Pharma shares in Q2 2026, an estimated $784K.
  • UroGen Pharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2057 holding.
  • John Overdeck first reported a position in UroGen Pharma in Q4 2017 and has held it in 17 quarters since.
  • John Overdeck's UroGen Pharma position peaked at $7.7M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.